ClinicalTrials.gg
RecruitingNCT07393958ENDOLIRALUpdated Oct 30, 2026

Impact of Food Supplementation on Quality of Life in Patients With Endometriosis and Pelvic Pain.

An interventional study of Food supplement (T1675) and Placebo in Endometriosis (Diagnosis), sponsored by Arafarma Group, S.A.. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Arafarma Group, S.A. · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Oct 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Endometriosis with a site in Spain — 13 open to participants now, 15 under way, none of them phase 3. Endometriosis · Spain.

Planned enrollment
21st of 33
60 · median 90
Started
2026
with 2 others
No phase
18 of 42
8 open now
Primary completion
2027-08
later than 10 of 14 live
Registered
40th of 42
by date

Among the 42 studies in Endometriosis with a site in Spain, this one is the 21st largest by planned enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2026, is one of 18 with no phase, reaches primary completion later than 10 of the 14 other live ones, and was the 40th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

13 of the 42 studies in Endometriosis with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Endometriosis with a site in Spain, or all of them as a file.
02

Study summary

This study examines whether the food supplement Doliral can improve quality of life and reduce pelvic pain in women with endometriosis, compared with placebo, over several weeks.

Read the detailed description

Patients included into the study will be randomized into two treatment groups (30:30 patients). 30 patients will be treated with the food supplement and 30 patients will be treated with placebo. Both groups will be stratified by the presence or absence of hormonal therapy. Patients will be required to attend 6 study visits (selection visit, baseline or visit 0, and visits 1, 2, 3 and final or visit 4). Patients will complete a daily endometriosis symptom diary, which also includes a record of anti-inflammatory and paing medication use. Study treatment will be administred at Visit 0 or Baseline until Visit 4 or Final. At the study visits, patients will be requested to confirm the pain intensity through the VAS scale for different endometriosis pain types. They will be also requested to complete several questionnaires about quality of life.

03

Conditions studied

  • Endometriosis (Diagnosis)

Keywords

  • pain
  • QoL
  • food supplement
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women of reproductive age with diagnosed endometriosis stage I, II, or III, according to the American Society for Reproductive Medicine (ASRM) classification.
  • Women with a diagnosis of endometriosis confirmed by laparoscopy or, in the absence of laparoscopy, by magnetic resonance imaging (MRI) and/or ultrasound.
  • Presence of pelvic pain (VAS > 4) during the last three months.
  • No indication for surgical intervention at the time of inclusion in the study.
  • Patients who are able to provide .

Exclusion criteria

Exclusion Criteria:

  • Patients under 18 years of age.
  • Use of analgesic or anti-inflammatory pharmacological treatment, except for ibuprofen at doses up to 600 mg/day or naproxen at doses up to 500 mg/day.
  • Surgery within the year prior to inclusion, performed for therapeutic purposes related to the pathology under study.
  • Initiation or discontinuation of hormone therapy within the three months prior to inclusion in the study.
  • Patients with known allergy or to Doliral®.
  • Pregnant or breastfeeding patients.
  • Patients on sick leave: > 1 year, or With no intention of returning to work, or Undergoing a disability or permanent incapacity assessment process.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Experimental (Food supplement-Doliral)

    Patient takes one buccal tablet per day.

    Dietary Supplement: Food supplement (T1675)

  • Placebo comparator
    Control (Placebo)

    Patient takes one buccal tablet per day.

    Other: Placebo

Interventions

  • Dietary supplementFood supplement (T1675)

    Doliral is the food supplement, which is the investigational product at this study.

  • OtherPlacebo

    Placebo is the control treatment.

06

What researchers measure

Primary outcomes

  1. To measure the improvement of the quality of life.

    Patients complete EQ-5D-5L questionnaire at Day 1 (baseline visit), at 2 weeks (Visit 1), at 4 weeks (Visit 2), at 8 weeks (Visit 3) and at 12 weeks (Visit 4). This questionnaire measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression and health status. These five dimensions have 5 response levels: No problems, slight problems, moderate problems, severe problems and extreme problems. This questionnaire also has a Visual Analogue Scale from 0 (worse health status) to 100 (best health status).

    Time frame: From baseline visit to the final visit at 12 weeks.

  2. To measure the improvement of the quality of life.

    Patients complete the Endometriosis Health Profile 30 Questionnaire at Day 1 (baseline visit), at 2 weeks (Visit 1), at 4 weeks (Visit 2), at 8 weeks (Visit 3) and at 12 weeks (Visit 4). This questionnaire evaluates six domains: pain, control and powerlessness, emotional well-being, social support and self-image. These scales are converted into a 0-100 score, 0 is best health status and 100 is worse quality of life.

    Time frame: From baseline visit to the final visit at 12 weeks.

  3. To measure the improvement of the quality of life.

    Patients complete PGI-I (Patient Global Impression of Improvement) scale at Day 1 (baseline visit), at 2 weeks (Visit 1), at 4 weeks (Visit 2), at 8 weeks (Visit 3) and at 12 weeks (Visit 4). PGI-I is a Likert scale from 1 (significantly better) to 7 (significantly worse).

    Time frame: From baseline visit to the final visit at 12 weeks.

  4. To measure the improvement in pain intensity.

    To describe the type and intensity of pain using a Visual Analogue Scale (VAS) at at Day 1 (baseline visit), at 2 weeks (Visit 1), at 4 weeks (Visit 2), at 8 weeks (Visit 3) and at 12 weeks (Visit 4). It is measured the change of these results from baseline visit to the final visit. Also patients complete a symptoms diary between visits. For each symptom, the patient will record intensity (on a scale from 1 to 10).

    Time frame: From baseline visit to the final visit at 12 weeks.

Secondary outcomes

  1. Compare the reduction in the need for prescription and dosage of anti-inflammatory and analgesic pharmacological treatment.

    Patients will complete the use of inflammatory and analgesic pharmacological treatment (name, dose and time) in a diary between visits.

    Time frame: From baseline visit to the final visit at 12 weeks.

  2. To measure the incidence of clinically relevant episodes

    To assess and destribe the type, intensity and relationship with investigational product of clinically relevant episodes at Day 1 (baseline visit), at 2 weeks (Visit 1), at 4 weeks (Visit 2), at 8 weeks (Visit 3) and at 12 weeks (Visit 4).

    Time frame: From Visit 1 (2 weeks) to Visit 4 or Final (12 weeks).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Aug 2027, 17 months after the start.

Of 214 interventional studies with no phase under Endometriosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's planned 17 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Aug 2026 → Aug 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2026
First posted
Feb 6, 2026
StartActual
Feb 26, 2026
Primary completionEst.
Aug 1, 2027was Aug 2026
CompletionEst.
Sep 15, 2027was Sep 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 1, 2026→Aug 1, 2027
Oct 30, 2026
Study completion
Sep 15, 2026→Sep 15, 2027
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Primary completion Aug 1, 2026→Aug 1, 2027
    Study completion Sep 15, 2026→Sep 15, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07393958
Lead sponsor
Arafarma Group, S.A.
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Feb 26, 2026
Primary completion
Aug 1, 2027 (estimated)
Completion
Sep 15, 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Tamara Rodríguez Araya, Dr
Contact
tlrodriguez@clinic.cat
+34 932 27 54 00
TAMARA RODRIGUEZ ARAYA, Dr
principal investigator · Hospital Clinic of Barcelona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion